Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome

Bone Marrow Transplantation volume 46, pages 150–151 (2011)Cite this article

Subjects

Several factors that predict the prognosis of patients who have received allo-SCT have been identified. Recent studies have suggested that iron overload is one of the important predictors of the outcome of allo-SCT.1, 2, 3, 4, 5 We studied prognostic variables (including pre-SCT serum ferritin level) in patients receiving SCT and devised a new scoring system to predict the outcome of SCT in patients with AML or myelodysplastic syndrome (MDS).

We analyzed 119 patients with AML or MDS who underwent allogeneic SCT at Kanagawa Cancer Center between January 2000 and December 2008. Their characteristics are summarized in Table 1. The following pre-SCT and post-SCT variables were investigated as predictors of the outcome: age, sex, pre-SCT serum ferritin level, disease type, disease status at transplantation (first or second CR and refractory anemia were defined as standard risk, while all others were defined as high risk), conditioning regimen, GVHD prophylaxis, donor type and stem cell source, corticosteroid therapy within 100 days after SCT, acute GVHD and chronic GVHD. The log-rank test was used for comparison of Kaplan–Meier curves and the Cox regression model was used for multivariate analyses. Data were analyzed as of July 31, 2009.

Table 1 Patients’ characteristics
Full size table

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586–4588.

    Article  CAS  Google Scholar 

  2. Kataoka K, Nannya Y, Hangaishi A, Imai Y, Chiba S, Takahashi T et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 195–204.

    Article  Google Scholar 

  3. Lee JW, Kang HJ, Kim EK, Kim H, Shin HY, Ahn HS . Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant 2009; 44: 793–797.

    Article  CAS  Google Scholar 

  4. Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42: 799–805.

    Article  CAS  Google Scholar 

  5. Kanda J, Mizumoto C, Kawabata H, Ichinohe T, Tsuchida H, Tomosugi N et al. Clinical significance of serum hepcidin levels on early infectious complications in allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 956–962.

    Article  CAS  Google Scholar 

  6. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Ritz J et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 28–35.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

    T Tachibana, H Takasaki, M Tanaka, A Maruta & H Kanamori

  2. Department of HSCT Data Management and Biostatistics, School of Medicine, Nagoya University, Nagoya, Japan

    R Hyo

  3. Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Y Ishigatsubo

Authors
  1. T Tachibana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Takasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Maruta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Hyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Ishigatsubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Kanamori.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tachibana, T., Takasaki, H., Tanaka, M. et al. Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome. Bone Marrow Transplant 46, 150–151 (2011). https://doi.org/10.1038/bmt.2010.62

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.62

This article is cited by

Search

Advanced search

Quick links